NEW YORK (GenomeWeb News) – Cancer Genetics this week launched its joint venture with the Mayo Clinic. Called OncoSpire Genomics, the new company will develop and commercialize diagnostic tests that leverage next-generation sequencing. OncoSpire is 50-50 owned by Cancer Genetics, which went public in April, and Mayo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.